Average Co-Inventor Count = 3.77
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Merck Sharp + Dohme Corp. (12 from 2,405 patents)
2. Novacyte Therapeutics Company., Ltd (2 from 2 patents)
3. Harvard College (1 from 2,963 patents)
4. Merck Canada Inc. (1 from 40 patents)
5. Novacyte, Inc. (1 from 1 patent)
16 patents:
1. 12343399 - Polymer linkers and their uses
2. 11529422 - Polymer linkers and their uses
3. 10583196 - Polymer linkers and their uses
4. 9775839 - 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
5. 9682978 - 2,6,7 substituted purines as HDM2 inhibitors
6. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors
7. 9351965 - Indazole derivatives useful as ERK inhibitors
8. 9242984 - Pyrazolyl derivatives as Syk inhibitors
9. 9206142 - Anilinopiperazine derivatives and methods of use thereof
10. 8999957 - Heterocyclic compounds as ERK inhibitors
11. 8962611 - Substituted imidazopyridines as HDM2 inhibitors
12. 8846657 - Substituted imidazopyridines as HDM2 inhibitors
13. 8609675 - Fused Tricyclic Compounds as novel mTOR inhibitors
14. 8591943 - Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
15. 8318735 - 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors